$Humacyte (HUMA.US)$ Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs Humacyte (Nasdaq: HUMA) and Pluristyx have expanded their partnership to advance the development of the BioVascular Pancreas (BVP™), designed to treat insulin-dependent diabetes. Pluristyx will provide gene-edited PluriBank™ iPSC lines with blocked Human Leukocyte Antigen (HLA) markers expression, using their clinical-grade Mad7 gene editing technology. ...
$Humacyte (HUMA.US)$Reuters 1 min ago Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs
$Humacyte (HUMA.US)$ FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military. The fact that we have a +10 billion $ runway is just nice to know.
1
Report
104983812
:
so it means it got plenty of rooms to rise?
Humacyte Stock Forum
Hospitals Already Adopting Humacyte's Revolutionary Bioengineered Blood Vessel - What Makes Symvess Different?
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
Humacyte (Nasdaq: HUMA) and Pluristyx have expanded their partnership to advance the development of the BioVascular Pancreas (BVP™), designed to treat insulin-dependent diabetes. Pluristyx will provide gene-edited PluriBank™ iPSC lines with blocked Human Leukocyte Antigen (HLA) markers expression, using their clinical-grade Mad7 gene editing technology.
...
1 min ago
Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs
FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military.
The fact that we have a +10 billion $ runway is just nice to know.
No comment yet